Document:

ex10_1.htm

    
      

    

    
      
      

      

      SUBSCRIPTION
AGREEMENT

      

      

      

      Houston
American Energy Corp.

      801
Travis

      Suite
1425

      Houston,
Texas  77002

      

      

      Gentlemen:

      

      The
undersigned (the "Investor") hereby confirms its
agreement with Houston American Energy Corp., a Delaware corporation (the "Company"), as
follows:

      

      1.           
 This Subscription Agreement, including the Terms and Conditions for
Purchase of Shares attached hereto as Annex I
(collectively, this "Agreement"), is made as of the
date set forth below between the Company and the Investor.

      

      2.         
   The Company represents and warrants that it has authorized the
sale and issuance to certain investors of up to an aggregate of _______
(___,000) Shares (the "Shares") of its Common Stock,
par value $0.001 per share (the "Common Stock"), for a purchase
price of $_____ per share (the "Purchase Price").

      

      3.          
  The Company represents and warrants that the offering and sale of
the Shares (the "Offering") are being made
pursuant to (a) an effective Registration Statement on Form S-3 (Registration
No. 333-161319) (the "Registration Statement") filed
by the Company with the Securities and Exchange Commission (the "Commission"), including the
Prospectus contained therein (the "Base Prospectus"), (b) if
applicable, certain "free writing prospectuses" (as that term is defined in Rule
405 under the Securities Act of 1933, as amended (the "Act")), that have been or will
be filed with the Commission and delivered to the Investor on or prior to the
date hereof (the "Issuer Free
Writing Prospectus"), containing certain supplemental information
regarding the Shares, the terms of the Offering and the Company, and (c) a
Prospectus Supplement (the "Prospectus Supplement" and,
together with the Base Prospectus, the "Prospectus") containing
certain supplemental information regarding the Shares and terms of the Offering
that has been or will be (i) filed with the Commission, and (ii) delivered to
the Investor (or made available to the Investor by the filing by the Company of
an electronic version thereof with the Commission).

      

      4.      
      The Company and the Investor agree that the
Investor will purchase from the Company and the Company will issue and sell to
the Investor the Shares set forth below for the aggregate purchase price set
forth below.  The Shares shall be purchased pursuant to the Terms and
Conditions for Purchase of Shares attached hereto as Annex I and
incorporated herein by this reference as if fully set forth
herein.  The Investor acknowledges that the Offering is not being
underwritten by the placement agents (the "Placement Agents") named in
the Prospectus Supplement and that there is no minimum offering
amount.

      

      5.           
 The manner of settlement of the Shares purchased by the Investor shall be
determined by such Investor as follows (check
one):

      

      
        	
                [____]
      A.

              	
                Delivery
      by crediting the account of the Investor's prime broker (as specified by
      such Investor on Exhibit A
      annexed hereto) with the Depository Trust Company ("DTC") through its
      Deposit/Withdrawal At Custodian ("DWAC") system, whereby
      Investor's prime broker shall initiate a DWAC transaction on the Closing
      Date using its DTC participant identification number, and released by
      Standard Registrar and
      Transfer Company, Inc., the Company's transfer agent (the "Transfer Agent"), at the
      Company's direction.  NO LATER THAN ONE (1) BUSINESS
      DAY AFTER THE EXECUTION OF THIS AGREEMENT BY THE INVESTOR AND THE COMPANY,
      THE INVESTOR SHALL:

              

      

      

      
        	
                 
      

              	
                (I)

              	
                DIRECT
      THE BROKER-DEALER AT WHICH THE ACCOUNT OR ACCOUNTS TO BE CREDITED WITH THE
      SHARES ARE MAINTAINED TO SET UP A DWAC INSTRUCTING THE TRANSFER AGENT TO
      CREDIT SUCH ACCOUNT OR ACCOUNTS WITH THE SHARES,
  AND

              

      

      
        
           

        

        
           

          
            

          

        

        
           

        

      

      
        	
                 
      

              	
                (II)

              	
                REMIT
      BY WIRE TRANSFER THE AMOUNT OF FUNDS EQUAL TO THE AGGREGATE PURCHASE PRICE
      FOR THE SHARES BEING PURCHASED BY THE INVESTOR TO THE FOLLOWING
      ACCOUNT:

              

      

      

      

      Bank Name: JPMorgan
Chase Bank, N.A.

      ABA #
111000614

      Account
Name: Houston American Energy Corp.

      Account
Number: 801497553

      

        –
OR –

      

      
        	
                [____]
      B.

              	
                Delivery
      versus payment ("DVP") through DTC (i.e., on the
      Closing Date, the Company shall deliver Shares registered in the
      Investor's name and address as set forth below and released by the
      Transfer Agent to the Investor through DTC at the Closing directly to the
      account(s) at Knight Capital Markets LLC ("Knight") identified by
      the Investor; upon receipt of such Shares, KNIGHT shall promptly
      electronically deliver such Shares to the Investor, and simultaneously
      therewith payment shall be made by KNIGHT by wire transfer to the
      Company).  NO
      LATER THAN ONE (1) BUSINESS DAY AFTER THE EXECUTION OF THIS AGREEMENT BY
      THE INVESTOR AND THE COMPANY, THE INVESTOR
  SHALL:

              

      

      

      
        	
                 
      

              	
                (I)

              	
                NOTIFY
      KNIGHT OF THE ACCOUNT OR ACCOUNTS AT KNIGHT TO BE CREDITED WITH THE SHARES
      BEING PURCHASED BY SUCH INVESTOR,
AND

              

      

      
        	
                 
      

              	
                (II)

              	
                CONFIRM
      THAT THE ACCOUNT OR ACCOUNTS AT KNIGHT TO BE CREDITED WITH THE SHARES
      BEING PURCHASED BY THE INVESTOR HAVE A MINIMUM BALANCE EQUAL TO THE
      AGGREGATE PURCHASE PRICE FOR THE SHARES BEING PURCHASED BY THE
      INVESTOR.

              

      

      

      IT IS THE INVESTOR'S
RESPONSIBILITY TO (A) MAKE THE NECESSARY WIRE TRANSFER OR CONFIRM THE PROPER
ACCOUNT BALANCE IN A TIMELY MANNER AND (B) ARRANGE FOR SETTLEMENT BY WAY OF DWAC
OR DVP IN A TIMELY MANNER.  IF THE INVESTOR DOES NOT DELIVER THE
AGGREGATE PURCHASE PRICE FOR THE SHARES OR DOES NOT MAKE PROPER ARRANGEMENTS FOR
SETTLEMENT IN A TIMELY MANNER, THE SHARES MAY NOT BE DELIVERED AT CLOSING TO THE
INVESTOR OR THE INVESTOR MAY BE EXCLUDED FROM THE CLOSING
ALTOGETHER.

      

      6.          
  The Investor represents that, except as set forth below, (a) it has
had no material relationship (exclusive of any investments by the Investor in
the Company's securities) within the past three years with the Company or
persons known to it to be affiliates of the Company, (b) it is not a FINRA
member or an Associated Person of a FINRA member (as such term is defined under
the NASD Membership and Registration Rules Section 1011) as of the Closing, and
(c) neither the Investor nor any group of Investors (as identified in a public
filing made with the Commission) of which the Investor is a part in connection
with the Offering of the Shares, acquired, or obtained the right to acquire, 20%
or more of the Common Stock (or securities convertible into or exercisable for
Common Stock) or the voting power of the Company on a post-transaction
basis.  Exceptions:

      

      The representations above
are made to the knowledge of the signatory below.

      (If no
exceptions, write "none." If left blank, response will be deemed to be
"none.")

      

      7.          
  The Investor represents that it has received (or otherwise had made
available to it by the filing by the Company of an electronic version thereof
with the Commission) the Base Prospectus which is a part of the Company's
Registration Statement, the documents incorporated by reference therein and any
Issuer Free Writing Prospectus (collectively, the "Disclosure Package"), prior to
or in connection with the receipt of this Agreement.  The Investor
acknowledges that, prior to the delivery of this Agreement by the Investor to
the Company, the Investor will receive certain additional information regarding
the Offering, including pricing information (the "Offering Information"). Such
information may be provided to the Investor by any means permitted under the
Act, including the Prospectus Supplement, a free writing prospectus and oral
communications.

      
        
           

        

        
           

          
            

          

        

        
           

        

      

      8.          
  The Investor
acknowledges that the Company has made available to the Investor such materials
relating to the business, finances and operations of the Company's Columbian
operators, Hupecol, LLC and S-K Energy Co. LTD, as requested by the Investor and
available to the Company.  The Investor acknowledges that the Company's
Columbian assets consist exclusively of minority, non-operator project interests
in the Columbian assets owned and operated by Hupecol, LLC, and a 25%
non-operated working interest in the Columbian assets owned and operated by S-K
Energy Co. LTD.  Investor acknowledges that the Company's passive
investments in such Columbian assets constitute the principal assets and
operations of the Company, and as a result, the Company's financial results are
directly affected by the independent strategies and decisions of Hupecol, LLC
and S-K Energy Co. LTD.

      

      9.          
  No offer by the Investor to buy Shares will be accepted and no part
of the Purchase Price will be delivered to the Company until the Investor has
received the Offering Information and the Company has accepted such offer by
countersigning a copy of this Agreement, and any such offer may be withdrawn or
revoked, without obligation or commitment of any kind, at any time prior to the
Company (or Placement Agents on behalf of the Company) sending (orally, in
writing or by electronic mail) notice of its acceptance of such
offer.  An indication of interest will involve no obligation or
commitment of any kind until the Investor has been delivered the Offering
Information and this Agreement is accepted and countersigned by or on behalf of
the Company.

      

      

      [Remainder
of Page Left Blank Intentionally.  Signature Page
Follows.]

      
        
           

        

        
           

          
            

          

        

        
           

        

      

      Number of
Shares: ___________________

      

      Purchase
Price Per Share: $ ____________

      

      Aggregate
Purchase Price: $ __________

      

      

      Please
confirm that the foregoing correctly sets forth the agreement between us by
signing in the space provided below for that purpose.

      

      

      
        	
                 

              	
                Dated
      as of:  ______________ __, 2009

              
	 
      	 
      	 
      
	 
      	 
      	 
      
	 
      	 
      
	 
      	
                INVESTOR

              
	 
      	 
      	 
      
	 
      	
                By:

              	 
      
	 
      	
                Print
      Name:

              	 
      
	 
      	
                Title:

              	 
      
	 
      	
                Address:

              	 
      
	 
      	 
      	 
      
	 
      	 
      
	 
      	 
      	 
      
	 
      	
                E-mail:

              	 
      
	 
      	
                Phone:

              	 
      

      

      

      

      Agreed
and Accepted

      this ___
day of ______________, 2009:

      

      

      HOUSTON
AMERICAN ENERGY CORP.

      

      

      
        	
                By:

              	 
      	 
      
	
                Name:

              	 
      	 
      
	
                Title:

              	 
      	 
      

      

      
        
           

        

        
           

          
            

          

        

        
           

        

      

      ANNEX I

      

      TERMS
AND CONDITIONS FOR PURCHASE OF SHARES

      

      1.          
  Authorization and
Sale of the Shares.  Subject to the terms and conditions of
this Agreement, the Company has authorized the sale of the Shares.

      

      2.          
  Agreement to Sell and Purchase the Shares; Placement
Agents.

      

      2.1           At
the Closing (as defined in Section 3.1), the
Company will sell to the Investor, and the Investor will purchase from the
Company, upon the terms and conditions set forth herein, the number of Shares
set forth on the last page of the Agreement to which these Terms and Conditions
for Purchase of Shares are attached as Annex I (the "Signature Page") for the
aggregate purchase price therefor set forth on the Signature Page.

      

      2.2           The
Company proposes to enter into substantially this same form of Subscription
Agreement with certain other investors (the "Other Investors") and expects
to complete sales of Shares to them.  The Investor and the Other
Investors, if any, are hereinafter sometimes collectively referred to as the
"Investors," and this
Agreement and the Subscription Agreements executed by the Other Investors are
hereinafter sometimes collectively referred to as the "Agreements."

      

      2.3           Investor
acknowledges that the Company has agreed to pay Global Hunter Securities LLC,
Knight Capital Markets LLC, Pali Capital, Inc. and Source Capital Group Inc.
(the "Placement Agents")
a fee (the "Placement
Fee") in respect of the sale of Shares to the Investor.

      

      2.4           The
Company has entered into a Placement Agency Agreement, dated December 1, 2009
(the "Placement
Agreement"), with the Placement Agents that contains certain
representations, warranties, covenants and agreements of the Company that may be
relied upon by the Investor, which shall be a third party beneficiary
thereof.  The Company represents and warrants that a true and correct
copy of the Placement Agreement is attached hereto as Exhibit
B.  Except with respect to the material terms and conditions of
the transactions contemplated by this Agreement, the Placement Agreement and any
other documents or agreements contemplated hereby or thereby, the Company
confirms that neither it nor any other person acting on its behalf has provided
the Investor or any Other Investor or its respective agents or counsel with any
information that constitutes or could reasonably be expected to constitute
material, non-public information.   The Company understands and
confirms that the Investor will rely on the foregoing representations in
effecting transactions in securities of the Company.

      

      3.         
   Closings and Delivery of the Shares and Funds.

      

      3.1           Closing.  The completion of
the purchase and sale of the Shares (the "Closing") shall occur at a
place and time (the "Closing
Date") to be specified by the Company and the Placement Agents (such
Closing Date to be the third business day following the date of this signed
Agreement), and of which the Investors will be notified in advance by the
Placement Agents, in accordance with Rule 15c6-1 promulgated under the
Securities Exchange Act of 1934, as amended (the "Exchange Act").  At
the Closing, (a) the Company shall cause to be delivered to the Investor the
number of Shares set forth on the Signature Page registered in the name of the
Investor or, if so indicated on the Investor Questionnaire attached hereto as
Exhibit A, in
the name of a nominee designated by the Investor and (b) the aggregate purchase
price for the Shares being purchased by the Investor will be delivered by or on
behalf of the Investor to the Company.

      

      3.2           Conditions to the
Obligations of the Parties.

      

      (a)           Conditions
to the Company's Obligations.  The Company's
obligation to issue and sell the Shares to the Investor shall be subject to: (i)
the delivery by the Investor, in accordance with the provisions of this
Agreement, of the purchase price for the Shares being purchased hereunder as set
forth on the Signature Page and (ii) the accuracy of the representations and
warranties made by the Investor in this Agreement and the fulfillment of those
undertakings of the Investor in this Agreement to be fulfilled prior to the
Closing Date.

      
        
           

        

        
           

          
            

          

        

        
           

        

      

      (b)           Conditions
to the Investor's Obligations.  The Investor's
obligation to purchase the Shares will be subject to (i) the delivery by the
Company of the Shares in accordance with the provisions of this Agreement, (ii)
the accuracy of the representations and warranties made by the Company and the
fulfillment of those undertakings of the Company to be fulfilled prior to the
Closing Date, including without limitation, those contained in the Placement
Agreement, (iii) the satisfaction of the conditions to the closing set forth in
the Placement Agreement, and to the condition that the Placement Agents, shall
not have: (x) terminated the Placement Agreement pursuant to the terms thereof
or (y) determined that the conditions to the closing in the Placement Agreement
have not been satisfied.  The Investor's obligations are expressly not
conditioned on the purchase by any or all of the Other Investors of the Shares
that they have agreed to purchase from the Company.  The Investor
understands and agrees that, in the event that Global Hunter Securities LLC, as
lead placement agent, in its sole discretion determines that the conditions to
closing in the Placement Agreement have not been satisfied or if the Placement
Agreement may be terminated for any other reason permitted by the Placement
Agreement, then Global Hunter Securities LLC, as lead placement agent, may, but
shall not be obligated to, terminate such Agreement, which shall have the effect
of terminating this Subscription Agreement pursuant to Section 14
below.

      

      3.3           Delivery
of Funds.

      

      (a)           DWAC
Delivery.  If the Investor elects to settle the Shares
purchased by such Investor through DTC's Deposit/Withdrawal at Custodian ("DWAC") delivery system, no later
than one (1) business day after the execution of this Agreement by the Investor
and the Company, the Investor shall remit by wire transfer the amount of
funds equal to the aggregate purchase price for the Shares being purchased by
the Investor to the following account designated by the Company:

      

      Bank Name: JPMorgan
Chase Bank, N.A.

      ABA #
111000614

      Account
Name: Houston American Energy Corp.

      Account
Number: 801497553

      

      Such
funds shall be held in escrow by the Company until the Closing upon the
satisfaction of the conditions set forth in Section 3.2(b) hereof.

      

      (b)           Delivery Versus Payment
through The Depository Trust Company.  If the Investor elects
to settle the Shares purchased by such Investor by delivery versus payment
through DTC, no later
than one (1) business day after the execution of this Agreement by the Investor
and the Company, the Investor shall confirm that the account or accounts
at KNIGHT to be credited with the Shares being purchased by the Investor have a
minimum balance equal to the aggregate purchase price for the Shares being
purchased by the Investor.

      

      3.4           Delivery
of Shares.

      

      (a)           DWAC
Delivery.  If the Investor elects to settle the Shares
purchased by such Investor through DTC's DWAC delivery system, no later
than one (1) business day after the execution of this Agreement by the Investor
and the Company, the Investor shall direct the broker-dealer at which the
account or accounts to be credited with the Shares being purchased by such
Investor are maintained, which broker/dealer shall be a DTC participant, to set
up a DWAC instructing Standard
Registrar and Transfer Company, Inc., the Company's Transfer Agent, to
credit such account or accounts with the Shares.  Such DWAC
instruction shall indicate the settlement date for the deposit of the Shares,
which date shall be provided to the Investor by KNIGHT.  At the
Closing, the Company shall direct the Transfer Agent to credit the Investor's
account or accounts with the Shares pursuant to the information contained in the
DWAC.

      

      (b)           Delivery Versus Payment
through The Depository Trust Company.  If the Investor elects
to settle the Shares purchased by such Investor by delivery versus payment
through DTC, no later
than one (1) business day after the execution of this Agreement by the Investor
and the Company, the Investor shall notify KNIGHT of the account or
accounts at KNIGHT to be credited with the Shares being purchased by such
Investor.  On the Closing Date, the Company shall deliver the Shares
to the Investor through DTC directly to the account(s) at KNIGHT identified by
Investor and simultaneously therewith payment shall be made by KNIGHT by wire
transfer to the Company.

      
        
           

        

        
           

          
            

          

        

        
           

        

      

      4.           Representations,
Warranties and Covenants of the Investor.

      

      The
Investor acknowledges, represents and warrants (as of the date hereof) to, and
agrees with, the Company and the Placement Agents that:

      

      4.1           The
Investor (a) is knowledgeable, sophisticated and experienced in making, and is
qualified to make decisions with respect to, investments in shares presenting an
investment decision like that involved in the purchase of the Shares, including
investments in securities issued by the Company and investments in comparable
companies, (b) has answered all questions on the Signature Page and the Investor
Questionnaire and the answers thereto are true and correct as of the date hereof
and will be true and correct as of the Closing Date and (c) in connection with
its decision to purchase the number of Shares set forth on the Signature Page,
has received and is relying only upon the Disclosure Package and the documents
incorporated by reference therein and the Offering Information and the
representations, warranties, covenants and agreements of the Company contained
in the Placement Agreement.

      

      4.2           (a)
No action has been or will be taken in any jurisdiction outside the United
States by the Company or the Placement Agents that would permit an offering of
the Shares, or possession or distribution of offering materials in connection
with the issue of the Shares in any jurisdiction outside the United States where
action for that purpose is required, (b) if the Investor is outside the United
States, it will comply with all applicable laws and regulations in each foreign
jurisdiction in which it purchases, offers, sells or delivers Shares or has in
its possession or distributes any offering material, in all cases at its own
expense and (c) none of the Placement Agents is authorized to make or has made
any representation, disclosure or use of any information in connection with the
issue, placement, purchase and sale of the Shares, except as set forth or
incorporated by reference in the Base Prospectus, any Issuer Free Writing
Prospectus or the Prospectus Supplement.

      

      4.3           (a)
The Investor is either an individual or an entity duly organized, validly
existing and in good standing under the laws of the jurisdiction of its
organization and has full right, power, authority and capacity to enter into
this Agreement and to consummate the transactions contemplated hereby and has
taken all necessary action to authorize the execution, delivery and performance
of this Agreement, and (b) this Agreement constitutes a valid and binding
obligation of the Investor enforceable against the Investor in accordance with
its terms, except as enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting creditors' and
contracting parties' rights generally and except as enforceability may be
subject to general principles of equity (regardless of whether such
enforceability is considered in a proceeding in equity or at law) and except as
to the enforceability of any rights to indemnification or contribution that may
be violative of the public policy underlying any law, rule or regulation
(including any federal or state securities law, rule or
regulation).  The Investor's execution, delivery and performance of
this Agreement and the consummation by it of the transactions contemplated
hereby do not and will not (i) conflict with or violate any provision of the
Investor's certificate or articles of incorporation, bylaws or other
organizational or charter documents, or (ii) conflict with or result in a
violation of any law, rule, regulation, order, judgment, injunction, decree or
other restriction of any court or governmental authority to which the
Investor  is subject (including federal and state securities laws and
regulations), or by which any property or asset of the Investor is bound or
affected.

      

      4.4           The
Investor understands that nothing in this Agreement, the Prospectus or any other
materials presented to the Investor in connection with the purchase and sale of
the Shares constitutes legal, tax or investment advice.  The Investor
has consulted such legal, tax and investment advisors and made such
investigation as it, in its sole discretion, has deemed necessary or appropriate
in connection with its purchase of Shares.

      

      4.5           Since
the time at which a Placement Agent first contacted the Investor about the
Offering, the Investor has not disclosed any information regarding the Offering
to any third parties (other than its legal, accounting and other advisors) and
has not engaged in any transactions involving the securities of the Company
(including, without limitation, any Short Sales involving the Company's
securities).  The Investor covenants that it will (i) maintain the
confidentiality of all information acquired as a result of the transactions
contemplated herein and (ii) not engage in any purchases or sales of the
securities of the Company (including Short Sales), in each case prior to the
time that the transactions contemplated by this Agreement are publicly
disclosed.  The Investor agrees that it will not use any of the Shares
acquired pursuant to this Agreement to cover any short position in the Common
Stock if doing so would be in violation of applicable securities
laws.  For purposes hereof, "Short Sales" include, without
limitation, all "short sales" as defined in Rule 200 promulgated under
Regulation SHO under the Exchange Act, whether or not against the box, and all
types of direct and indirect stock pledges, forward sales contracts, options,
puts, calls, short sales, swaps, "put equivalent positions" (as defined in Rule
16a-1(h) under the Exchange Act) and similar arrangements (including on a total
return basis), and sales and other transactions through non-US broker dealers or
foreign regulated brokers.

      
        
           

        

        
           

          
            

          

        

        
           

        

      

      5.           Survival of Representations,
Warranties and Agreements; Third Party
Beneficiary.  Notwithstanding any investigation made by any
party to this Agreement or by the Placement Agents, all covenants, agreements,
representations and warranties made by the Company and the Investor herein and,
with respect to the Company, in the Placement Agreement, will survive the
execution of this Agreement, the delivery to the Investor of the Shares being
purchased and the payment therefor.

      

      6.           Notices.  All
notices, requests, consents and other communications hereunder will be in
writing, will be mailed (a) if within the domestic United States by first-class
registered or certified airmail, or nationally recognized overnight express
courier, postage prepaid, or by facsimile or (b) if delivered from outside the
United States, by International Federal Express or facsimile, and (c) will be
deemed given (i) if delivered by first-class registered or certified mail
domestic, three business days after so mailed, (ii) if delivered by nationally
recognized overnight carrier, one business day after so mailed, (iii) if
delivered by International Federal Express, two business days after so mailed
and (iv) if delivered by facsimile, upon electric confirmation of receipt and
will be delivered and addressed as follows:

       
 

      
        	
                 
      

              	
                (a)

              	
                if to the Company,
      to:

              

      

      

      Houston
American Energy Corp.

      801
Travis

      Suite
1425

      Houston,
Texas  77002

      Attention:  John
F. Terwilliger

      Facsimile
No.:  713-222-6440

      

      

      (b)              
if to the Investor, at its address on the Signature Page hereto, or at such
other address or addresses as may have been furnished to the Company in
writing.

      

      7.           Changes.  This
Agreement may not be modified or amended except pursuant to an instrument in
writing signed by the Company and the Investor.  Any modification or
amendment to Section 2 (Representations and Warranties of the Company), Section
5 (Conditions of Placement Agents' Obligations), Section 6(f) (Representations
and Agreements to Survive Delivery), or Section 10 (Persons Entitled to Benefit
of Agreement) of the Placement Agreement, and any modification or amendment to
the Placement Agreement that is material and adverse to the Investor, shall
require the prior written consent of the Investor.

      

      8.          
  Headings.  The
headings of the various sections of this Agreement have been inserted for
convenience of reference only and will not be deemed to be part of this
Agreement.

      

      9.           
 Severability.  In
case any provision contained in this Agreement should be invalid, illegal or
unenforceable in any respect, the validity, legality and enforceability of the
remaining provisions contained herein will not in any way be affected or
impaired thereby.

      

      10.          Governing Law.  This
Agreement will be governed by, and construed in accordance with, the internal
laws of the State of New York, without giving effect to the principles of
conflicts of law that would require the application of the laws of any other
jurisdiction.  Except as set forth below, no proceeding may be
commenced, prosecuted or continued in any court other than the courts of State
of New York located in the City and County of New York or the United States
District Court for the Southern District of New York, which courts shall have
jurisdiction over the adjudication of such matters, and the parties hereby
consent to the jurisdiction of such courts and personal service with respect
thereto.  All parties hereby waive all right to trial by jury in any
proceeding (whether based upon contract, tort or otherwise) in any way arising
out of or relating to this Agreement.  All parties agree that a final
judgment in any such proceeding brought in any such court shall be conclusive
and binding upon each party and may be enforced in any other courts in the
jurisdiction of which a party is or may be subject, by suit upon such
judgment.

      
        
           

        

        
           

          
            

          

        

        
           

        

      

      11.          Counterparts.  This
Agreement may be executed in two or more counterparts, each of which will
constitute an original, but all of which, when taken together, will constitute
but one instrument, and will become effective when one or more counterparts have
been signed by each party hereto and delivered to the other
parties.  Delivery of an executed counterpart by facsimile or portable
document format (.pdf) shall be effective as delivery of a manually executed
counterpart thereof.

      

      12.          Confirmation of
Sale.  The Investor acknowledges and agrees that such
Investor's receipt of the Company's signed counterpart to this Agreement,
together with the Prospectus Supplement (or the filing by the Company of an
electronic version thereof with the Commission), shall constitute written
confirmation of the Company's sale of Shares to such Investor.

      

      13.          Press Release.  The
Company and the Investor agree that, prior to the opening of the Nasdaq Global
Market in New York City on the business day immediately after the date hereof,
the Company shall (i) issue a press release announcing the Offering and
disclosing all material information regarding the Offering and (ii) file a
Current Report on Form 8-K with the Commission disclosing all material
information regarding the Offering and including the Placement Agreement and a
form of this Agreement as exhibits thereto.  From and after the
issuance of such press release and the filing of such Current Report on Form
8-K, the Company shall have publicly disclosed all material, non-public
information delivered to any of the Investors by the Company or any person
acting on its behalf, including, without limitation, the Placement Agents, in
connection with the transactions contemplated by this Agreement, the Placement
Agreement and any other documents or agreements contemplated hereby or
thereby.  The Company shall not identify the name of any Investor or
any affiliate of any investment adviser of such Investor in any press release or
public filing, or otherwise publicly disclose the name of any Investor or any
affiliate of investment adviser of such Investor, without such Investor's prior
written consent, unless required by law or the rules and regulations of a
national securities exchange, provided, however, that, if permitted by
applicable law, regulation, legal or judicial process, promptly after becoming
aware of any request or requirement to so disclose (a "Disclosure Requirement"), and
in any event prior to any such disclosure, the Company will provide such
Investor with notice of such request or requirement so that such Investor may at
its election seek a protective order or other appropriate remedy and the Company
will fully cooperate with such Investor's efforts to obtain the same; provided,
further, however, if, absent the entry of such a protective order or other
remedy, the Company is compelled by applicable law, rule or regulation or a
court order, subpoena, similar judicial process, regulatory agency or stock
exchange rule to disclose such Investor's name, the Company may disclose only
that portion of such information that the Company is so compelled to disclose
and will use its reasonable efforts to obtain assurance that confidential
treatment will be accorded to that portion of such information that is being
disclosed.  As of the date hereof, the Company is not aware of any
Disclosure Requirement.

      

      14.          Termination.  In the
event that the Placement Agreement is terminated by the Placement Agents
pursuant to the terms thereof, this Agreement shall terminate without any
further action on the part of the parties hereto.

      

      15.          Fees and
Expenses.  Each party shall pay the fees and expenses of its
advisers, counsel, accountants and other experts, if any, and all other expenses
incurred by such party incident to the negotiation, preparation, execution,
delivery and performance of this Agreement.

      
        
           

        

        
           

          
            

          

        

        
           

        

      

      Exhibit
A

      

      HOUSTON
AMERICAN ENERGY CORP.

      

      INVESTOR
QUESTIONNAIRE

      

      Pursuant
to Section 3 of
Annex I to the
Agreement, please provide us with the following information:

      

      

      
        	
                1.

              	
                The
      exact name that your Shares are to be registered in. You may use a nominee
      name if appropriate:

              	
                 

              
	
                2.

              	
                The
      relationship between the Investor and the registered holder listed in
      response to item 1 above:

              	
                 

              
	
                3.

              	
                The
      mailing address of the registered holder listed in response to item 1
      above:

              	
                 

              
	
                4.

              	
                The
      Social Security Number or Tax Identification Number of the registered
      holder listed in the response to item 1 above:

              	
                 

              
	
                5.

              	
                Name
      of DTC Participant (broker-dealer at which the account or accounts to be
      credited with the Shares are maintained):

              	
                 

              
	
                6.

              	
                DTC
      Participant Number:

              	
                 

              
	
                7.

              	
                Name
      of Account at DTC Participant being credited with the
    Shares:

              	
                 

              
	
                8.

              	
                Account
      Number at DTC Participant being credited with the Shares:

              	
                 

              
	
                9.

              	
                EIN
      Number:DISTRIBUTION AGREEMENT

    

    

    THIS
DISTRIBUTION AGREEMENT (this "Agreement"), dated as of
November 15, 2009, is entered into by and between Oncura, Inc., a corporation
organized and existing under the laws of Delaware, having offices located at
3350 Ridge Road, Arlington Heights, IL 60004 ("Oncura") and IsoRay Medical, Inc., a
corporation organized under the laws of the State of Delaware, having offices
located at 350 Hills Street, Suite 106, Richland, Washington 99354 ("IsoRay").

    

    PRELIMINARY
STATEMENTS

    

    IsoRay
desires to: (i) obtain the non exclusive right to distribute the I-125 Products
in the Territory and (ii) use the Oncura Trademarks for the I-125 Products in
the Territory in connection with the foregoing, and Oncura desires to grant such
rights to IsoRay, on the terms and conditions set forth in this
Agreement.

    

    NOW,
THEREFORE, in consideration of the foregoing preliminary statements and the
mutual agreements and covenants set forth herein, the Parties hereby agree as
follows:

    

    
      	
              1

            	
              DEFINITIONS.

            

    

    

    As used
in this Agreement, the following terms shall have the meanings set forth in this
Section 1 unless context dictates otherwise:

    

    1.1 "Accelerated Arbitration
Provisions" shall have the meaning assigned to such term in Section
12.13(b).

    

    1.2 "Affiliate" of any Person
means any other Person directly or indirectly controlling, controlled by or
under common control with such Person; provided that for purposes of this
Agreement, neither IsoRay nor any of its Subsidiaries shall be deemed an
Affiliate of Oncura and neither Oncura nor any of its Subsidiaries shall be
deemed an Affiliate of IsoRay. For the purposes of this definition, "control" when used with
respect to any Person, means the possession, directly or indirectly, of the
power to direct or cause the direction of the management and policies of such
Person, whether through the ownership of voting securities, by contract or
otherwise; and the terms "controlling" and "controlled" have meanings
correlative to the foregoing.

    

    1.3 "Breaching Party" shall have
the meaning assigned to such term in Section 10.2.

    

    1.4 "cGMP" shall mean current
Good Manufacturing Practice as defined in Part 820 of Title 21 of the U.S. Code
of Federal Regulations, as may be amended from time to time, or any successor
thereto.

    

    1.5 "Confidential Information"
shall have the meaning assigned to such term in Section 7.1.

    

    1.6 "Effective Date" shall mean the date set
forth in the introductory paragraph of the Agreement.

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

    

      

       

    

    1.7 "FDA" shall mean the United
States Food and Drug Administration, or any successor thereto.

    

    1.8 "Field" shall mean all
medical device applications for human health.

    

    1.9 "Finished Product" shall mean
any formulation or dosage of an I-125 Product in finished form, including,
without limitation, any product labeling or other package inserts or materials
required by the applicable Regulatory Authority(ies) and, when used in the
plural, shall mean all formulations and dosages of an I-125 Product in finished
form, including, without limitation, all product labeling and other package
inserts and materials required by the applicable Regulatory
Authority(ies).

    

    1.10
"GAAP" shall mean
generally accepted accounting principles in the United States, consistently
applied by the Party at issue.

    

    1.11
"I-125 Products" shall
mean the brachytherapy products containing I-125 listed on Exhibit
1.11.

    

    1.12
"Inability to Supply"
shall have the meaning assigned to such term in Section 5.11(a).

    

    1.13
"Indemnitee" shall have
the meaning assigned to such term in Section 9.4.

    

    1.14
"Infringement" shall
have the meaning assigned to such term in Section 6.3(a).

    

    1.15
"Invention" shall mean
any new or useful process, manufacture, compound, composition of matter,
improvements, discoveries, claims, formulae, processes, trade secrets,
technologies and know-how (including confidential data and Confidential
Information), to the extent relating to, derived from and useful for the
manufacture, use or sale of a I-125 Product (including, without limitation, the
formulation, delivery or use thereof in the Field), including, without
limitation, synthesis, preparation, recovery and purification processes and
techniques, control methods and assays, chemical data, toxicological and
pharmacological data and techniques, clinical data, medical uses, product forms
and product formulations and specifications, whether patentable or unpatentable,
that (except for purposes of the definitions of Know-How and Patents set forth
herein in Sections 1.18 and 1.25, respectively) is conceived or first reduced to
practice or demonstrated to have utility during the term of this
Agreement.

    

    1.16
"IsoRay" shall have the
meaning assigned to such term in the introductory paragraph.

    

    1.17
"Know-How" shall mean
any and all unpatented Inventions that are generated, owned or controlled by
Oncura at any time before or during the term of this Agreement to the extent
relating to, derived from and useful for the manufacture, use or sale of the
I-125 Products in the Field in any country in the Territory.

    

    1.18
"Long-Term Inability to
Supply" shall have the meaning assigned to such term in Section
5.11(c).

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    

      

    

     

    1. 19
"Manufacturing
Standards" shall mean, with respect to any I-125 Product, cGMP and such
additional manufacturing specifications or standards as may be established by
mutual agreement of IsoRay and Oncura from time to time.

    

    1.20
"Non-Breaching Party"
shall have the meaning assigned to such term in Section 10.2.

    

    1.21
"Oncura" shall have the
meaning assigned to such term in the introductory paragraph.

    

    1.22
"Oncura Trademarks"
shall mean those Trademarks that are owned by Oncura or which Oncura otherwise
has the right to use in the Territory.

    

    1.23
"Party" shall mean
IsoRay or Oncura, as the case may be, and, when used in the plural, shall mean
IsoRay and Oncura.

    

    1.24
"Patents" shall mean
the patents and patent applications set forth on Exhibit 1.25, together with any
patents that may issue therefrom in any country in the Territory, and any other
patents or patent applications in any country in the Territory owned by or
exclusively licensed to Oncura during the term of this Agreement that cover any
Inventions to the extent relating to, derived from and useful for the
manufacture, use or sale of the I-125 Products in the Field in any country in
the Territory, including any and all extensions, renewals, continuations,
continuations-in-part, divisions, patents-of-additions, reissues, supplementary
protection certificates or foreign counterparts of any of the
foregoing.

    

    1.25
"Person" shall mean an
individual or a corporation, partnership, association, trust, or any other
entity or organization, including a government or political subdivision or an
agency or instrumentality thereof.

    

    1.26
"Registration" shall
mean, with respect to each country in the Territory, approval of the
Registration Application for any I-125 Product filed in such country, including,
where applicable outside of the United States, pricing or reimbursement approval
by the Regulatory Authority in such country.

    

    1.27
"Registration
Application" shall mean a 510K Application under the United States
Federal Food, Drug and Cosmetics Act and the regulations promulgated thereunder,
or a comparable filing for Registration in a country, in each case with respect
to a I-125 Product for application in the Field in the Territory.

    

    1.28
"Regulatory Authority"
shall mean the FDA in the U.S., and any health regulatory authority(ies)
in any country in the Territory that is a counterpart to the FDA and holds
responsibility for granting regulatory marketing approval for an I-125 Product
in such country, and any successor(s) thereto.

    

    1.29
"Specifications" shall
mean, with respect to an I-125 Product, the specifications for such I-125
Product as agreed upon by IsoRay and Oncura, in consideration of the regulatory
requirements in each country in the Territory, as may be amended from time to
time.

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    

     

    1.30
"Subsidiary" means,
with respect to any Person, any corporation or other entity of which a majority
of the capital stock or other ownership interests having ordinary voting power
to elect a majority of the board of directors or other persons performing
similar functions are at the time directly or indirectly owned by such
Person.

    

    1.31
"Technology" shall mean
the Valid Claims and Know-How, collectively.

    

    1.32
The "Territory" shall
mean the United States and Canada.

    

    1.33
"Testing Methods" shall
have the meaning assigned to such term in Section 5.7(c).

    

    1.34
"Third Party" shall
mean any Person who or which is neither a Party nor an Affiliate of a
Party.

    

    1.35
"Trademarks" shall mean
the trademarks registered to Oncura or IsoRay, as applicable.

    

    1.36
"United States" or
"U.S." shall mean the
United States of America, including its possessions and
territories.

    

    1.37
"Valid Claim" shall
mean any claim of any Patents issued or pending in a country in the Territory
relating to, derived from or useful for the use and sale of the I-125 Products
in the Field, which claim has not been held invalid or unenforceable by decision
of a court or other governmental agency of competent jurisdiction, unappealable
or unappealed within the time allowed for appeal, and which is not admitted to
be invalid through disclaimer or otherwise not admitted by the Party holding
such Patent to be invalid.

    

    
      	
              2

            	
              GRANT
      OF RIGHTS.

            

    

    

    2.1.          Rights Granted to IsoRay.
Subject to the terms and conditions of this Agreement, Oncura hereby grants to
IsoRay a non-exclusive right to distribute the I-125 Products in the
Territory.

    

    2.2.         Oncura
Trademarks; Logos.

    

    (a)           Oncura
hereby grants IsoRay the non-exclusive right to use the Oncura Trademarks in the
Territory in connection with the I-125 Products, subject to the provisions of
this Agreement and for the term hereof. Solely in connection with IsoRay's
promotion, distribution and sale of I-125 Products in the Territory, IsoRay
shall market the I-125 Products throughout the Territory under the applicable
Oncura Trademarks for the relevant country in the  Territory. The use
of Oncura Trademarks by IsoRay shall be subject to the terms and conditions set
forth in this Section 2.2. In the event that IsoRay's rights under Section 2.1
are terminated, IsoRay's rights to use the Oncura Trademarks pursuant to this
Section 2.2 shall terminate as well.

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    

    
    

    (b)           Whenever
IsoRay uses Oncura Trademarks in advertising or in any other manner in
connection with the I-125 Products, IsoRay shall clearly indicate Oncura's
ownership of the Oncura Trademarks. When using Oncura Trademarks under this
Agreement, IsoRay agrees to comply with all laws pertaining to trademarks in
force at any time in the Territory.

    

    (c)           If
necessary in any country in the Territory to permit IsoRay to use Oncura
Trademarks, Oncura shall make application to register IsoRay as a permitted user
or registered user of the Oncura Trademarks and, if necessary, or if requested
by Oncura, IsoRay undertakes to join in such application and to take such action
as may be necessary or requested by Oncura to implement such application or
retain, enforce or defend the Oncura Trademarks. If necessary in any country in
the Territory to maintain Oncura's rights in the Oncura Trademarks, IsoRay shall
enter into a registered user agreement or permitted user agreement regulating
its use of Oncura Trademarks.

    

    (d)           IsoRay
acknowledges that Oncura is the owner of the Oncura Trademarks. IsoRay shall not
at any time do, cause to be done, or permit any act or thing inconsistent with,
contesting or in any way impairing or tending to impair such ownership. IsoRay
agrees that all use of Oncura Trademarks by IsoRay shall inure to the benefit of
and be on behalf of Oncura. IsoRay acknowledges that nothing in this Agreement
shall give IsoRay any right, title or interest in Oncura Trademarks other than
the right to use the Oncura Trademarks in accordance with this Agreement. IsoRay
agrees that it will not challenge the title or ownership of Oncura to any of the
Oncura Trademarks or attack or contest the validity of any of the Oncura
Trademarks.

    

    (e)           Oncura
shall register and maintain, or cause to be registered and maintained, the
Oncura Trademarks in the Territory during the term of this Agreement at Oncura's
sole expense. If any Party learns of any actual, alleged or threatened
unauthorized use or other infringement of any Oncura Trademarks by others in the
Territory, such Party agrees to promptly notify the other Party of such
unauthorized use or other infringement. Oncura shall use all commercially
reasonable efforts to retain, enforce and defend the Oncura Trademarks in the
Territory.

    

    (f)           To
the extent permitted by law, all labeling, packaging, literature, promotional
material and advertising for any I-125 Product to be marketed, distributed or
sold in any country in the Territory shall contain Oncura's name and logo with
comparable prominence as the name and logo used by IsoRay. To the extent
practicable, or as required by applicable law to protect the Oncura Trademarks,
IsoRay shall include on any material bearing any Oncura Trademarks an
acknowledgement that such Trademark is the property of Oncura.

    

    
      	
              3 

            	
              DISTRIBUTION
      AND PROMOTION.

            

    

    

    3.1.         Generally. IsoRay shall use
commercially reasonable efforts to promote and sell the I-125 Products in the
Territory.

    

    3.2.         Responsibilities;
Rights.

    

    (a)           IsoRay,
either itself and/or by and through its Affiliates, shall be responsible for and
shall have the rights granted under Section 2.1.

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

    

      
  

    

    (b)           In
connection with its responsibility for distribution, marketing and sales of the
I-125 Products in the Territory, IsoRay shall provide all sales force
(including, without limitation, sales administration and training), order entry,
customer service, reimbursement management, medical affairs, medical
information, marketing (including all advertising and promotional expenditures),
warehousing, physical distribution, invoicing, credit and collections,
production forecasting and other related facilities and services necessary or
desirable for such distribution, marketing and sales.

    

    (c)           IsoRay
agrees to refrain from making any claims about the I-125 Products which do not
conform to the Specifications, directions for use, product labeling, and
applicable Registrations for such I-125 Products.  IsoRay further
agrees to immediately cease, following written notice by Oncura, making any
claims which Oncura reasonably objects to with respect to the I-125
Products.

    

    3.3           Distribution and Marketing
Costs. From and after the Effective Date, IsoRay shall be solely
responsible for its distribution and marketing costs of whatever type, except as
expressly provided otherwise in this Agreement.

    

    
      	
              4 

            	
              PAYMENTS.

            

    

    

    4.1           Mode of Payment. IsoRay shall
make all payments required under this Agreement in U.S. Dollars.

    

    4.2           Records Retention. Each Party
shall keep complete and accurate records pertaining to the purchase and sale of
I-125 Products for a period of three calendar years after the year in which such
purchases and sales occurred, and in sufficient detail to permit the other Party
to confirm the accuracy of each of the foregoing.

    

    4.3           Taxes.  In the event
that IsoRay is required to withhold any tax to the tax or revenue authorities in
any country in the Territory regarding any payment to Oncura due to the laws of
such country, such amount shall be deducted from the payment to be made and
IsoRay shall promptly notify Oncura of such withholding and, within a reasonable
amount of time after making such deduction, furnish Oncura with copies of any
tax certificate or other documentation evidencing such withholding. Each Party
agrees to cooperate with the other Party in claiming exemptions from such
deductions or withholdings under any agreement or treaty from time to time in
effect.

    

    
      	
              5 

            	
              MANUFACTURE
      AND SUPPLY.

            

    

    

    5.1.           Supply Obligations. Except as
mutually agreed by Oncura and IsoRay, commencing on the Effective Date, and
thereafter during the term of this Agreement, subject to the terms and
conditions of this Section 5, Oncura shall be responsible for the manufacture
and supply of all of IsoRay's requirements of I-125 Products for commercial
distribution in the  Territory pursuant to this Agreement, but IsoRay
may purchase I-25 Products from suppliers other than Oncura at any time. IsoRay
shall place orders for the I-125 Products, and, at IsoRay's option, either have
Oncura ship directly to the final customers for such I-125 Products or to a
third party loading service.

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

    

      
    

    

    5.2           Processing of I-125
Products.  Oncura shall be solely responsible for ensuring
compliance with all applicable requirements of the Regulatory Authorities within
the Territory. Oncura shall use commercially reasonable efforts to ensure that
all services, facilities and goods used in connection with such processing
comply with the applicable Manufacturing Standards in effect from time to
time.

    

    5.3           Loading Services. The Parties
acknowledge and agree that IsoRay's final customers for the I-125 Products shall
have sole discretion over which third party loading services they may choose to
use to process the I-125 Products, and Oncura agrees to ship the I-125 Products
to any third party loading service specified on a valid purchase order submitted
by IsoRay.

    

    5.4           Orders for
Products.  IsoRay shall place its firm non-custom
order with Oncura at least
one (1) day in advance of the delivery date, setting forth amounts, delivery
dates and shipping instructions, including delivery addresses, with respect to
each shipment of the I-125 Product (collectively, the "Deliverables"). IsoRay shall
place custom load or calibrated
service orders three (3) business days in advance of the delivery date.
IsoRay shall place custom
stranded service orders five (5) business days in advance of the delivery
date.  All orders must be placed by 4:00 PM
CT.  Oncura shall be required to accept such orders from
IsoRay, subject to the other terms and conditions of this Agreement. IsoRay's
orders shall be made pursuant to purchase orders which are in a form mutually
acceptable to Oncura and IsoRay, to the extent that such form is not
inconsistent with the terms of this Agreement.  IsoRay shall notify
Oncura as soon as possible of an increase in its requirements for a given
Deliverable of greater than 300% of the orders for that Deliverable shipped in
the preceding calendar month.

    

    5.5           Delivery. With respect to
exact shipping dates, Oncura shall use all reasonable commercial efforts to ship
or cause to be shipped quantities of Deliverables that Oncura is obligated to
supply pursuant to Section 5.4 on the dates specified in IsoRay's purchase
orders submitted and accepted in accordance with Section 5.4. Notwithstanding
any inconsistent term that may be specified on IsoRay's purchase order for a
Deliverable, all Deliverables to be delivered pursuant to this Agreement shall
be delivered in accordance with this Section 5.5, suitably packed in bulk
containers for shipment, and marked for shipment to the final destination point
indicated in the purchase order. The shipping packaging used in connection with
such deliveries shall be in accordance with cGMP with respect to protection of
the Deliverable during transportation, taking into consideration the mode(s) of
transport IsoRay has elected to use for each such shipment, the final
destination point of each such shipment and reasonable expectations regarding
shipment time duration and possible delays associated therewith. Transportation
of Deliverables may be made by rail, road, air, sea, inland waterway or by a
combination of such modes of transport. Title and risk of loss shall transfer to
IsoRay upon delivery to the carrier or Person designated by IsoRay.

    

    5.6           Purchase
Price; Invoicing.

    

    (a)           The
purchase price for all Deliverables supplied pursuant to this Section 5 for
commercial use in the Territory shall be as indicated for each Deliverable on
Exhibit 5.6.

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

    

       

    (b)           Oncura
shall submit invoices to IsoRay for Deliverables ordered promptly after
shipment. Payments shall be made by IsoRay within 30 days after its receipt of
the invoice. IsoRay has no obligation to pay for any shipment of Deliverables
that (i) Oncura and IsoRay agree does not to meet the Specifications and/or
Manufacturing Standards, or (ii) in accordance with Section 5.8, IsoRay has
found not to meet the Specifications and/or Manufacturing Standards while such
findings have not been contradicted by independent laboratory testing. Upon
Oncura's receipt of a notice from IsoRay claiming that a shipment of
Deliverables does not meet the Specifications and/or applicable Manufacturing
Standards, the time period for payment of such shipment shall toll until such
time as such non-conformity questions regarding such shipment or such batch are
resolved in accordance with Section 5.8. All relevant terms of Section 4 with
respect to payments shall apply to the payment of invoices for the supply of the
Deliverables.

    

    5.7           Conformity;
Specifications; Quality Control.

    

    (a)           All
quantities of Deliverables supplied by Oncura pursuant to this Section 5 will
comply in all material respects with the Specifications and applicable
Manufacturing Standards and shall adhere in all material respects to all
applicable governmental laws and regulations relating to the manufacture, sale
and shipment of each shipment of the Deliverable at the time it is shipped by
Oncura hereunder.

    

    (b)           Oncura
shall conduct, or cause to be conducted, quality control testing of the
Deliverables prior to shipment, in accordance with the Specifications and
applicable Manufacturing Standards as are in effect from time to time and such
other quality control testing procedures adopted by the Parties from time to
time (collectively, the "Testing Methods"). Initially
and until decided otherwise by the Parties, the Testing Methods shall include
all FDA and other Regulatory Authority required testing, based upon the delivery
location of the I-125 Products, and Oncura shall undertake all such tests.
Oncura shall retain records pertaining to such testing, which shall be made
available to IsoRay upon request. Each shipment of Deliverables hereunder shall
be accompanied by a certified quality control protocol and certificate of
analysis for each lot of Deliverables therein as well as such customs and other
documentation as is necessary or appropriate.

    

    (c)           All
units of Finished Product manufactured pursuant to this Agreement will comply in
all material respects with the applicable Manufacturing Standards and
specifications for Finished Products determined by the Parties and shall adhere
in all material respects to all applicable governmental laws and regulations
relating to the manufacture, sale and shipment of each Finished Product at the
time it is manufactured and distributed hereunder.

    

                   5.8           Acceptance/Rejection; Interim
Replacement.

    

    (a)           IsoRay
or its designated customer shall have the right to reject any shipment of
Deliverables made to it under this Agreement that does not meet the
Specifications and applicable Manufacturing Standards in any material respects
when received by it or its designee at such destination. All claims by IsoRay of
non-conforming Deliverables shall be deemed waived unless made by IsoRay in
writing and received by Oncura within 10 days of IsoRay's receipt or that of its
designee of the Deliverable.

     

    
      
        
        

      

      
        8

        
          

        

      

      
        
        

      

    

     

    
      

    

     

    (b)           All
claims of non-conforming Deliverables shall be accompanied by the allegedly
non-conforming Deliverable. Oncura shall promptly undertake its own analysis, in
accordance with the Testing Methods, of such Deliverable after receiving such
claim from IsoRay or its
designed Customer. If, after its own analysis, Oncura does not confirm such
non-conformity, the Parties agree to submit the disputed Deliverable to an
independent testing laboratory, to be agreed upon by the Parties, for testing in
accordance with the Testing Methods. Notwithstanding Section 12.13, the findings
of such laboratory shall be binding on the Parties, absent manifest error.
Expenses of such independent testing shall be borne by either Oncura or IsoRay,
with Oncura bearing all such expenses if the Deliverable is found to be
non-conforming, and IsoRay bearing all such expenses if the Deliverable is found
to be conforming. In the event that any Deliverable shipment or batch thereof is
ultimately agreed or found not to meet the Specifications and/or applicable
Manufacturing Standards, Oncura agrees to replace such shipment or batch with
conforming Deliverables and pay for all reasonable out of pocket expenses
incurred by IsoRay and its designee in connection with shipping and/or storing
such replacement Deliverables and storing the non-conforming Deliverables. Such
replacement shipment of Deliverables shall be treated as a new, additional
shipment of Deliverables (that will be separately invoiced by Oncura) for all
purposes, including measuring its conformity to the Specifications and
applicable Manufacturing Standards, and IsoRay's payment for such additional
shipment. In the event that any Deliverables shipment or batch thereof is
ultimately agreed or found to meet the Specifications and applicable
Manufacturing Standards, IsoRay shall accept and pay for such shipment or batch
in accordance with Section 5.6.

    

    (c)           Upon
Oncura's receipt of a claim that a shipment or batch thereof of Deliverables
does not meet the Specifications and/or applicable Manufacturing Standards,
Oncura shall use commercially reasonable efforts to replace such shipment or
batch thereof with an additional shipment of Deliverables that does conform to
such standards as soon as practicable.

    

               5.9           Inventory Management. Oncura
shall maintain inventory of I-125 Products in accordance with its usual and
customary inventory management practices that apply to its other brachytherapy
products.

    

    5.10       Shortage of
Supply.  Oncura shall notify IsoRay: (i) as promptly as
possible, but in no event more than ten days after Oncura's receipt of a firm
order from IsoRay as provided in Section 5.4, or (ii) immediately upon becoming
aware that Oncura is unable to supply the quantity of a Deliverable to IsoRay
that Oncura is required to supply hereunder, if Oncura is unable to supply such
quantities of Deliverables. In such event, Oncura shall implement all
commercially reasonable efforts to remedy such
shortage.  Notwithstanding anything in this Agreement to the contrary,
while such shortage is continuing, IsoRay may purchase I-125 Products from
suppliers other than Oncura.

    

    
      	
              6

            	
              PATENTS;
      TRADEMARKS.

            

    

    

    6.1           Ownership. Oncura shall have
all right, title and interest in and to its Patents, Know-How, and Trademarks,
whether in existence on the Effective Date or developed during the term of this
Agreement.

    

    6.2.        
Maintenance of the
Patents.  Oncura shall have full responsibility for, and shall
control the preparation and prosecution of, all patent applications and the
maintenance of all patents relating to the I-125 Products. Oncura shall pay all
costs and expenses of filing, prosecuting and maintaining its
Patents.

    
      
         

      

      
        9

        
          

        

      

      
         

      

    

    

    

                 6.3.    
      Patent Enforcement. If IsoRay
learns of an infringement, unauthorized use, misappropriation or ownership claim
or threatened infringement or other such claim (any of the foregoing, an "Infringement") by a Third
Party with respect to any Technology or any Trademark within the Territory,
IsoRay shall promptly notify Oncura and shall provide Oncura with available
evidence of such Infringement.

    

    
      	
              7

            	
              CONFIDENTIALITY;
      NON-SOLICITATION.

            

    

    

    7.1           Confidentiality; Exceptions.
Except to the extent expressly authorized by this Agreement or otherwise agreed
in writing, the Parties agree that, during the term of this Agreement and for
ten years thereafter, the receiving Party, its Affiliates and its licensees
shall, and shall ensure that their respective employees, officers, directors and
other representatives shall, keep completely confidential and not publish or
otherwise disclose and not use for any purpose any information furnished to it
or them by the disclosing Party, its Affiliates or its licensees or developed
under or in connection with this Agreement, except to the extent that it can be
established by the receiving Party by competent proof that such information: (i)
was already known to the receiving Party, other than under an obligation of
confidentiality, at the time of disclosure by the disclosing Party; (ii) was
generally available to the public or otherwise part of the public domain at the
time of its disclosure to the receiving Party; (iii) became generally available
to the public or was otherwise part of the public domain after its disclosure
and other than through any act or omission of the receiving Party in breach of
this Agreement; or (iv) was disclosed to the receiving Party, other than under
an obligation of confidentiality, by a Third Party who had no obligation to the
disclosing Party not to disclose such information to others (all such
information to which none of the foregoing exceptions applies, shall be deemed
"Confidential
Information").

    

    7.2           Exceptions to Obligation. The
restrictions contained in Section 7.3 shall not apply to Confidential
Information that: (i) is submitted by the recipient to governmental authorities
to facilitate the issuance of Registrations for the I-125 Products, provided
that reasonable measures shall be taken to assure confidential treatment of such
information; (ii) is provided by the recipient to Third Parties under
confidentiality provisions at least as stringent as those in this Agreement, for
consulting, manufacturing development, manufacturing, external testing, or
marketing trials; or (iii) is otherwise required to be disclosed in compliance
with applicable laws or regulations or order by a court or other regulatory body
having competent jurisdiction, including but not limited to the U.S. Securities
and Exchange Commission; provided that if a Party is required to make any such
disclosure of the disclosing Party's Confidential Information such Party will,
except where impracticable for necessary disclosures (for example, to health
authorities and the U.S. Securities and Exchange Commission), give reasonable
advance notice to the disclosing Party of such disclosure requirement and,
except to the extent inappropriate in the case of patent applications, will use
its best efforts to secure confidential treatment of such Confidential
Information required to be disclosed.

    

    7.3           Limitations on Use. Each Party
shall use, and cause each of its Affiliates and its licensees to use, any
Confidential Information obtained by such Party from the disclosing Party, its
Affiliates or its licensees, pursuant to this Agreement or otherwise, solely in
connection with the activities or transactions contemplated
hereby.

    
      
         

      

      
        10

        
          

        

      

      
         

      

    

    

    

    7.4           Remedies. Each Party shall be
entitled, in addition to any other right or remedy it may have, at law or in
equity, to an injunction, without the posting of any bond or other security,
enjoining or restraining the disclosing Party, its Affiliates and/or its
licensees from any violation or threatened violation of this Section
7.

    

    7.5           Non-Solicitation. Each Party
agrees that during the term of this Agreement, and for one (1) year thereafter,
it shall not (i) employ or retain on an independent contractor basis; or (i)
solicit for employment or for an independent contracting basis any person who
was, at any time during the immediately preceding twelve (12) month period,
employed by the other Party or any of its Affiliates.

    

    
      	
              8

            	
              REPRESENTATIONS
      AND WARRANTIES.

            

    

    

    8.1           Representations and Warranties of the
Parties. Each Party represents and warrants to the other Party, as of the
Effective Date, that:

    

    (a)           Such
Party is duly organized, validly existing and in good standing under the laws of
the jurisdiction of its incorporation and has full corporate power and authority
to enter into this Agreement and to carry out the provisions
hereof;

    

    (b)           Such
Party has taken all corporate action necessary to authorize the execution and
delivery of this Agreement and the performance of its obligations under this
Agreement and has full power and authority to enter into this Agreement and
perform its obligations under this Agreement;

    

    (c)           This
Agreement has been duly executed by such Party and constitutes a valid and
legally binding obligation of such Party, enforceable in accordance with its
terms, subject to and limited by: (i) applicable bankruptcy, insolvency,
reorganization, moratorium, and other laws generally applicable to creditors'
rights; and (ii) judicial discretion in the availability of equitable
relief;

    

    (d)           Such
Party is not required to obtain the consent, approval, order, or authorization
of any Third Party, or complete any registration, qualification, designation,
declaration or filing with, any federal, state, local, or provincial
governmental authority, in connection with the execution and delivery of this
Agreement and the performance by such Party of its obligations under this
Agreement, including, without limitation, the grant of rights to the other Party
pursuant to this Agreement, or such Party has done so;

    

    (e)           The
execution and delivery of this Agreement, and the performance by such other
Party of its obligations under this Agreement, including without limitation the
grant of rights to the other Party pursuant to this Agreement, will not: (i)
conflict with, nor result in any violation of or default under any such
instrument, judgment, order, writ, decree, contract or provision; (ii) give rise
to any event that results in the creation of any lien, charge or encumbrance
upon any assets of such Party or the suspension, revocation, impairment,
forfeiture or non-renewal of any material permit, license, authorization or
approval that applies to such Party, its business or operations or any of its
assets or properties; or (iii) conflict with any rights granted by such Party to
any Third Party or breach any obligation that such Party has to any Third
Party.

    
      
         

      

      
        11

        
          

        

      

      
         

      

    

    

    

    8.2           Representations and Warranties of
Oncura. Oncura represents and warrants  to IsoRay, as of the
Effective Date, that:

    

    (a)           Oncura
is the owner of, or has exclusive rights to, all of its Patents and the Oncura
Trademarks in existence on the Effective Date, and has the exclusive right to
grant the rights granted under this Agreement therefor. All of its Patents and
the Oncura Trademarks are valid, in
full force and effect and have been maintained to date, and, to the knowledge of
Oncura, are not the subject of any interference or opposition
proceedings;

    

    (b)           To
the knowledge of Oncura, Oncura (i) is not aware of any asserted or unasserted
claims, interferences, oppositions or demands of any Third Party against its
Technology or the Oncura Trademarks in existence as of the Effective Date, and
(ii) to the knowledge of Oncura, IsoRay’s practice of any invention claimed in
Oncura’s Patents or the exercise of any rights to its Technology or the Oncura
Trademarks as contemplated by this Agreement will not infringe any patent or
other intellectual property right of any Third Party;

    

    (c)           Oncura
has rights to all of its Know-How in existence on the Effective Date and the
right to grant all rights with respect thereto granted to IsoRay pursuant to
this Agreement;

    

    (d)           To
the knowledge of Oncura, IsoRay’s use of the I-125 Products in the Field, in
accordance with the terms of this Agreement, would not infringe upon or conflict
with any patent or other proprietary rights in the Territory of any Third Party;
and

    

    (e)           All
of the data and information provided to IsoRay relating to Oncura’s Technology
and the Oncura Trademarks is accurate and complete in all material respects and
contains no material errors or omissions.

    

    
      	
              9

            	
              RECALL; INDEMNIFICATION;
      INSURANCE.

            

    

    

    9.1           Investigation; Recall. In the
event that the Regulatory Authority in any country in the Territory shall allege
or prove that an I-125 Product does not comply with applicable rules and
regulations in such country, the Party so notified by the Regulatory Authority
shall notify the other Party immediately. Oncura shall conduct any appropriate
investigation and shall make a determination as to the disposition of any such
matter. If a Party is required or if Oncura should deem it appropriate to recall
any I-125 Product, Oncura shall bear the costs and expenses associated with such
recall, unless: the predominant cause of such recall results from IsoRay's
willful wrongdoing or negligence, in which case IsoRay shall bear all costs and
expenses associated with such recall.

    

    9.2.          Indemnification by IsoRay.
IsoRay shall indemnify, defend and hold harmless Oncura and its
Affiliates, and their respective directors, officers, employees and agents, from
and against any and all liabilities, damages, losses, costs and expenses
(including the reasonable fees of attorneys and other professionals) to the
extent arising out of or resulting from:

    

    (a)           negligence,
recklessness or wrongful intentional acts or omissions of IsoRay or its
Affiliates, and their respective directors, officers, employees and agents, in
connection with the fulfillment of IsoRay's rights or obligations under this
Agreement; or

    
      
         

      

      
        12

        
          

        

      

      
         

      

    

    

      

    

    

    (b)           any
breach of any representation or warranty made by IsoRay under Section
8.1.

    

    9.3.           Indemnification by Oncura.
Oncura shall indemnify, defend and hold harmless IsoRay and its respective
Affiliates, and their respective directors, officers, employees and agents, from
and against any and all liabilities, damages, losses, costs and expenses
(including the reasonable fees of attorneys and other professionals) to the
extent arising out of or resulting from:

    

    (a)           Negligence,
recklessness or wrongful intentional acts or omissions of Oncura or its
Affiliates, and their respective directors, officers, employees and agents, in
connection with the fulfillment of Oncura's rights or obligations under this
Agreement;

    

    (b)           Due
to any negligence, recklessness or wrongful intentional actsrict liability of,
Oncura Affiliates, and its respective directors, officers, employees and
agents.

    

    (c)           any
breach of any representation or warranty made by Oncura under Sections 8.1 and
8.2.

    

    9.4          Notice of Indemnification. In
the event that any Person (an "Indemnitee") entitled to
indemnification under Section 9.2 or 9.3 is seeking such indemnification, such
Indemnitee shall inform the indemnifying Party of the claim as soon as
reasonably practicable after such Indemnitee receives notice of such claim,
shall permit the indemnifying Party to assume direction and control of the
defense of the claim (including the sole right to settle it at the sole
discretion of the indemnifying Party, provided that such settlement does not
impose any obligation on, or otherwise adversely affect, the Indemnitee or any
of the other Parties) and shall cooperate as requested (at the expense of the
indemnifying Party) in the defense of the claim.

    

    9.5       
  Complete
Indemnification. As the Parties intend complete indemnification, all
costs and expenses incurred by an Indemnitee in connection with enforcement of
Sections 9.2 and 9.3 shall also be reimbursed by the indemnifying
Party.

    

    9.6          
Insurance. IsoRay agrees
to maintain throughout the term of this Agreement, for so long as it is selling
I-125 Products, at its own expense, liability insurance (including product
liability insurance) from a U.S. insurance company with a Moody's rating of
"Baa" or higher, including insurance against claims from bodily injury and
property damage and with a limit of insurance of at least five million Dollars
($5,000,000) per occurrence and at least five million Dollars ($5,000,000) in
the aggregate, including a contractual liability endorsement or a coverage
provision which provides coverage to IsoRay's obligations to indemnify
Oncura.  Oncura agrees to maintain throughout the term of this
Agreement, for so long as IsoRay is selling I-125 Products, at its own expense,
liability insurance (including product liability insurance) from a U.S.
insurance company with a Moody's rating of "Baa" or higher, including insurance
against claims from bodily injury and property damage and with a limit of
insurance of at least two million five hundred Dollars ($2,500,000) per
occurrence and at least five million Dollars ($5,000,000) in the aggregate,
including a contractual liability endorsement or a coverage provision which
provides coverage to Oncura's obligations to indemnify IsoRay.  Each
Party shall provide the other Party, within 30 days after the execution of this
Agreement, with certificates or other evidence of insurance required by this
Section 9.6. Each Party shall keep all insurance coverages required by this
Agreement in full force and effect for a period of [3 years] after the earlier of
the termination of this Agreement or the termination of IsoRay's right to
distribute I-125 Products manufactured by Oncura. Each of the Parties
understands and acknowledges that the other Party is entering into this
Agreement in part because of the foregoing insurance covenant.

    
      
         

      

      
        13

        
          

        

      

      
         

      

    

    

      

    

    

    
      	
              10 

            	
              TERM;
      TERMINATION.

            

    

    

    10.1      Term. This Agreement shall
become effective as of the Effective Date and, unless earlier terminated
pursuant to the other provisions of this Section 10, shall expire on the first
(1st) anniversary of the Effective Date. This Agreement will automatically renew
for additional terms of one (1) year each upon the first and each subsequent
anniversary of the Effective Date unless either Party provides the other Party
with notice in writing at least ninety (90) days prior to the expiration of the
term or any extension thereof that it does not desire to renew this
Agreement.

    

    10.2.     Termination for
Cause.  Either Party (as used in this subsection, the "Non-Breaching Party") may,
without prejudice to any other remedies available to it at law or in equity,
terminate this Agreement, in the event that the other party (as used in this
subsection, the "Breaching
Party") shall have materially breached or defaulted in the performance of
any of its material obligations hereunder, and such default shall have continued
for 60 days after written notice thereof was provided to the Breaching Party by
the Non-Breaching Party (or, if such default cannot be cured within such 60-day
period, if the Breaching Party does not commence and diligently continue actions
to cure such default during such 60-day period). Any such full or partial
termination shall become effective at the end of such 60-day period unless the
Breaching Party has cured any such breach or default prior to the expiration of
such 60-day period (or, if such default cannot be cured within such 60-day
period, if the Breaching Party has commenced and diligently continued actions to
cure such default). The right of the Non-Breaching Party to terminate this
Agreement in whole or in part, as provided in this Section 10.2 shall not be
affected in any way by its waiver or failure to take action with respect to any
previous default.

    

    10.3       Termination Without
Cause.  Either party may terminate this Contract without cause
at any time upon thirty (30) days’ prior written notice to the
other.

    

    10.4       Effect of Expiration or
Termination. If this Agreement expires pursuant to its terms or is
terminated by any Party pursuant to this Section 10, in addition to any other
remedies available to the Parties at law or in equity: (i) IsoRay shall promptly
transfer to Oncura copies of all data, reports, records and materials in its
possession or control that relate to the I-125 Products and return to Oncura all
relevant records and materials in its possession or control containing
Confidential Information of Oncura (provided that IsoRay may keep one copy of
such Confidential Information of Oncura for archival purposes only); (ii) IsoRay
shall transfer to Oncura, or shall cause its designee(s) to transfer to Oncura,
ownership of all Registration Applications, Registrations and other regulatory
filings made or filed for I-125 Products (to the extent that any are held in
IsoRay's or such designee(s)'s name), if permitted by applicable laws and
regulations; and (iii) Oncura shall promptly return to IsoRay all relevant
records and materials in Oncura's possession or control containing Confidential
Information of IsoRay (provided that Oncura may keep one copy of such
Confidential Information of IsoRay for archival purposes only).

    

    
      
        
           

        

        
          14

          
            

          

        

        
           

        

      

    

    

    
      

  

    10.5.   
   Accrued
Rights; Surviving Obligations.

    

    (a)           Termination,
relinquishment or expiration of this Agreement for any reason shall be without
prejudice to any rights that shall have accrued to the benefit of any Party
prior to such termination, relinquishment or expiration. Such termination,
relinquishment or expiration shall not relieve any Party from obligations which
are expressly indicated to survive termination or expiration of this Agreement.
All obligations which are not expressly indicated to survive termination or
expiration of this Agreement shall terminate upon the termination or expiration
of this Agreement.

    

    (b)           All
of the Parties' rights and obligations under, and/or the provisions contained
in, Sections 1, 4, 6.1, 6.3, 7, 9, 10.2, 10.4, and 12 shall survive termination,
relinquishment or expiration of this Agreement.

    

    
      	
              11 

            	
              FORCE
      MAJEURE.

            

    

    

    11.1        Events of Force Majeure.
Neither Party shall be held liable or responsible to the other Party nor be
deemed to be in default under, or in breach of any provision of, this Agreement
for failure or delay in fulfilling or performing any obligation of this
Agreement when such failure or delay is due to force majeure, and without the
fault or negligence of the Party so failing or delaying. For purposes of this
Agreement, force majeure is defined as causes beyond the control of the Party,
including, without limitation, acts of God; acts, regulations, or laws of any
government; war; civil commotion; destruction of production facilities or
materials by fire, flood, earthquake, explosion or storm; labor disturbances;
epidemic; and failure of public utilities or common carriers. In such event
IsoRay or Oncura, as the case may be, shall immediately notify the other Party
of such inability and of the period for which such inability is expected to
continue. The Party giving such notice shall thereupon be excused from such of
its obligations under this Agreement as it is thereby disabled from performing
for so long as it is so disabled and the 30 days thereafter. To the extent
possible, each Party shall use reasonable efforts to minimize the duration of
any force majeure.

    

    
      	
              12

            	
              MISCELLANEOUS.

            

    

    

    12.1        Relationship of Parties.
Nothing in this Agreement is intended or shall be deemed to constitute a
partnership, agency, employer-employee or joint venture relationship between the
Parties. No Party shall incur any debts or make any commitments for the other,
except to the extent, if at all, specifically provided herein.

    

    12.2         Assignment. No Party shall be
entitled to assign its rights or delegate its obligations hereunder without the
express written consent of the other Parties hereto, except that (i) IsoRay may
assign its rights and transfer its duties hereunder, without the consent of
Oncura, to a directly or indirectly wholly-owned subsidiary of IsoRay (provided
that, such subsidiary remains so owned, IsoRay guarantees the obligations of
such subsidiary under this Agreement in form and substance satisfactory to
Oncura, and no such assignment shall relieve IsoRay of any of its obligations
under this Agreement), (ii) Oncura may assign its rights and transfer its duties
hereunder, without the consent of IsoRay, to (A) a directly or indirectly
wholly-owned subsidiary of Oncura (provided that such subsidiary remains so
owned, Oncura guarantees the obligations of such subsidiary under this Agreement
in form and substance satisfactory to IsoRay, and no such assignment shall
relieve Oncura of any of its obligations under this Agreement), or (B) to any
assignee of all or substantially all of its business (or that portion of its
overall business of which this Agreement is a part (e.g. all of its
brachytherapy business)) or in the event of Oncura's merger, consolidation or
involvement in a similar transaction; provided that, in the case of (A) or (B),
the assignee agrees in writing to be bound by the terms of this Agreement. No
assignment or transfer shall be valid or effective unless done in accordance
with this Section 12.2.

    

    
      
        
           

        

        
          15

          
            

          

        

        
           

        

      

    

     

    
 

    12.3        Books and Records. Any books
and records to be maintained under this Agreement by a Party or its Affiliates
shall be maintained in accordance with GAAP.

    

    12.4.       Notice.  Any notice,
request or other communication required or permitted to be given under or in
connection with this Agreement shall be deemed to have been sufficiently given
if in writing and personally delivered or sent by facsimile transmission
(receipt verified) or overnight express courier service (signature required),
prepaid, to the Party for which such notice is intended, at the address set
forth for such Party below:

    

    In the
case of Oncura to:

    

    Attention:
James R. Clarkin, Director of Sales

    Facsimile
No: 484-530-3951

    Telephone
No: 516-873-1953

    

    With a
copy to:

    

    Attention:
Edmund Ranallo, Esq.

                     101
Carnegie Center

                      Princeton,
NJ 08540-6231

    Telephone:
609-514-6486

    Fax:
609-514-6574

    

    In the
case of IsoRay, to:

    

    IsoRay,
Inc.

    350 Hills
Street, Suite 106

    Richland,
WA 99354

    Attention:
Dwight Babcock, CEO

    Facsimile
No: (509) 375-3473

    Telephone
No: (509) 375-1202

    

    With a
copy to:

    

    Keller
Rohrback, PLC

    3101
North Central Avenue, Suite 1400

    Phoenix,
AZ 85012-2643

    Attention:
Stephen R. Boatwright, Esq.

    Facsimile
No: (602) 248-2822

    Telephone
No: (602) 230-6361

    

    
      
        
           

        

        
          16

          
            

          

        

        
           

        

      

    

     

    
  

    or to
such other address for such Party as it shall have specified by like notice to
the other Party, provided that notices of a change of address shall be effective
only upon receipt thereof. If delivered personally or by facsimile transmission,
the date of delivery shall be deemed to be the date on which such notice or
request was given. If sent by overnight express courier service, the date of
delivery shall be deemed to be the next business day after such notice or
request was deposited with such service.

    

    12.5         Use of Name. Except as
otherwise provided herein, IsoRay, on the one hand, and Oncura on the other
hand, shall not have any right, express or implied, to use in any manner the
name or other designation of the other or any other trade name, trademark or
logos of the other (including, without limitation, its Trademarks) for any
purpose in connection with the performance of this Agreement.

    

    12.6       
Public Announcements.
Except as required by applicable law, neither of the Parties shall make any
public announcement concerning this Agreement or the subject matter hereof
without the consent of the other Party.

    

    12.7       
Waiver. A waiver by any
Party of any of the terms and conditions of this Agreement in any instance shall
not be deemed or construed to be a waiver of such term or condition for the
future, or of any subsequent breach hereof. All rights, remedies, undertakings,
obligations and agreements contained in this Agreement shall be cumulative and
none of them shall be in limitation of any other remedy, right, undertaking,
obligation or agreement of any Party.

    

    12.8       
Compliance with Law.
Nothing in this Agreement shall be deemed to permit a Party to export, reexport
or otherwise transfer any I-125 Product sold under this Agreement without
compliance with applicable laws.

    

    12.9       
Severability. When
possible, each provision of this Agreement will be interpreted in such manner as
to be effective and valid under applicable law, but if any provision of this
Agreement is held to be prohibited by or invalid under applicable law, such
provision will be ineffective only to the extent of such prohibition or
invalidity, without invalidating the remainder of this Agreement.

    

    12.10     
Amendment. No amendment,
modification or supplement of any provisions of this Agreement shall be valid or
effective unless made in writing and signed by a duly authorized officer of each
Party.

    

    12.11     
Governing Law. This
Agreement shall be governed by and interpreted in accordance with the laws of
the State of Delaware without regard to conflicts of law
principles.

    

    12.12.     Arbitration.

    

    (a)           Except
as expressly otherwise provided in this Agreement, any dispute arising out of or
relating to the interpretation of any provisions of this Agreement or the
failure of any Party to perform or comply with any obligations or conditions
applicable to such Party pursuant to this Agreement shall be finally settled by
arbitration.  The arbitration shall be held in The State of Delaware
under the then current commercial arbitration rules of the American Arbitration
Association, in accordance with the terms set forth in this Section
12.13(a):

    

    
      
        
           

        

        
          17

          
            

          

        

        
           

        

      

    

    

    

       

    (i)           Unless
the Parties can agree on a single arbitrator, such arbitration shall be
conducted by three arbitrators, one appointed by each of Oncura and IsoRay and
the third selected by the first two appointed arbitrators. Each arbitrator shall
be a person with relevant experience in the medical device industry. Oncura and
IsoRay shall instruct such arbitrators to render a determination of any such
dispute within four months after the appointment of the third
arbitrator.

    

    (ii)           Any
award rendered by the arbitrators shall be final and binding upon the Parties.
Judgment upon any award rendered may be entered in any court having
jurisdiction, or application may be made to such court for a judicial acceptance
of the award and an order of enforcement, as the case may be. Each Party shall
pay its own expenses of arbitration, and the expenses of the arbitrators shall
be equally shared between Oncura and IsoRay unless the arbitrators assess as
part of their award all or any part of the arbitration expenses of a Party
(including reasonable attorneys' fees) against the other Party.

    

    (iii)           This
Section 12.13(a) shall not prohibit a Party from seeking injunctive relief from
a court of competent jurisdiction in the event of a breach or prospective breach
of this Agreement by any other Party which would cause irreparable harm to the
first Party.

    

    (b)           Whenever
a dispute arising out of or relating to the interpretation of any provisions of
this Agreement or the failure of any Party to perform or comply with any
obligations or conditions applicable to such Party pursuant to this Agreement
arises and such dispute is expressly designated as one to be resolved through
the Accelerated Arbitration Provisions, then such dispute shall be finally
settled by arbitration in accordance with the terms set forth in this subsection
(b) (the "Accelerated
Arbitration Provisions"). The arbitration shall be held in Richland,
Washington if instituted by Oncura, or in Princeton, NJ if instituted by IsoRay,
under the then current expedited procedures applicable to the then current
commercial arbitration rules of the American Arbitration
Association.

    

    (i)           Unless
the Parties can agree on a single arbitrator, such arbitration shall be
conducted by three arbitrators, one appointed by each of Oncura and IsoRay and
the third selected by the first two appointed arbitrators. Each arbitrator shall
be a person with relevant experience in the medical device industry. Oncura and
IsoRay shall instruct such arbitrators to render a determination of any such
dispute within 15 business days after the appointment of the third arbitrator.
Oncura and IsoRay must make their respective appointments within five business
days of notice being given to a Party by the other Parties of its intention to
resolve such dispute through these arbitration provisions. Such appointed
arbitrators must select the third arbitrator within five business days of the
last to occur of their respective appointments. The dispute shall be resolved by
submission of documents unless the arbitration panel determines that an oral
hearing is necessary. The arbitration panel shall, within the overall 15
business day time constraint, determine what shall be conclusively deemed to be
fair and appropriate deadlines for submitting documents and dates, if any, of
oral hearings.

    

    
      
        
           

        

        
          18

          
            

          

        

        
           

        

      

    

     

    

    
    

    (ii)           Any
award rendered by the arbitrators shall be final and binding upon the Parties.
Judgment upon any award rendered may be entered in any court having
jurisdiction, or application may be made to such court for a judicial acceptance
of the award and an order of enforcement, as the case may be. Each Party shall
pay its own expenses of arbitration, and the expenses of the arbitrators shall
be equally shared between Oncura and IsoRay unless the arbitrators assess as
part of their award all or any part of the arbitration expenses of a Party
(including reasonable attorneys' fees) against the other Party.

    

    (iii)           This
Section 12.13(b) shall not prohibit a Party from seeking injunctive relief from
a court of competent jurisdiction in the event of a breach or prospective breach
of this Agreement by any other Party which would cause irreparable harm to the
first Party.

    

    12.14     
Entire Agreement. This
Agreement constitutes the entire agreement among the Parties with respect to the
subject matter of this Agreement and supersedes all prior agreements and
understandings, both oral and written, among the Parties with respect to the
subject matter of this Agreement.

    

    12.15     
Parties in Interest. All
of the terms and provisions of this Agreement shall be binding upon, inure to
the benefit of and be enforceable by the Parties hereto and their respective
permitted successors and assigns.

    

    12.16     
Descriptive Headings.
The descriptive headings of this Agreement are for convenience only, and shall
be of no force or effect in construing or interpreting any of the provisions of
this Agreement.

    

    
      12.17     
Counterparts. This Agreement
may be executed simultaneously in any number\of
counterparts, any one of which need not contain the signature of more than one
Party but all such counterparts taken together shall constitute one and the same
agreement.

    

    

    
      12.18     
Rebates.  Eligible
rebates will be paid to designated IsoRay department by the [**].

    

     

    [Signature
Page Follows]

     

      
        

      

    

    
      
        [**]Certain
information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

      

       

    

    
      
        
        

      

      
        19

        
          

        

      

      
        
        

      

    

    

        

    IN
WITNESS WHEREOF, each of the Parties has caused this Agreement to be executed by
its duly authorized representative as of the day and year first above
written.

    

    
      
        	
                ISORAY
      MEDICAL, INC.

              
	 
      
	
                By:

              	
                /s/ Dwight Babcock

              
	
                Name:
      Dwight Babcock

              
	
                Title:
      Chief Executive Officer

              

      

    

    

    
      
        	
                ONCURA,
      Inc.

              
	 
      
	
                By:

              	
                /s/ Stephen Lightfoot

              
	
                Name:
      Stephen Lightfoot

              
	
                Title:  President,
      Oncura, Inc.

              

      

    

    

    
      
        
           

        

        
          20

          
            

          

        

        
           

        

      

    

     

    
     

    Exhibit
1.11

    

    I-125
PRODUCTS & PRICING*

    U.S.

    

    
      
        
          	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	
                  Quarterly
      Rebate

                
	
                  Product
      Code

                	 
      	
                  Product

                	 
      	
                  UOM

                	 
      	
                  UOM

                  Qty.

                	 
      	
                  Price

                	 
      	
                  Tier
      1

                  <
      [**]
      Seeds

                	 
      	
                  Tier
      2

                  [**]

                  Seeds

                	 
      	
                  Tier
      3

                  >
      [**]

                  Seeds

                
	
                  6711

                	 
      	
                  OncoSeed
      Individual Seed

                	 
      	
                  EA.

                	 
      	
                  1

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                
	
                  6711C

                	 
      	
                  OncoSeed
      Individual Calibrated Seed

                	 
      	
                  EA.

                	 
      	
                  1

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                
	
                  6717-I125NVG

                	 
      	
                  OncoSeed
      Loaded in Oncura Needle

                	 
      	
                  EA.

                	 
      	
                  1

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                
	
                  6719-I125NVG

                	 
      	
                  OncoSeed
      Loaded in Other Specified Needles

                	 
      	
                  EA.

                	 
      	
                  1

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                
	
                  6719-RL

                	 
      	
                  OncoSeed
      Preloaded in Needle (Vari-LoadTM)

                	 
      	
                  EA.

                	 
      	
                  1

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                
	
                  6715

                	 
      	
                  OncoSeed
      Sterile Convenience Pack (SCP)

                	 
      	
                  CTG.

                	 
      	
                  15

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                
	
                  6788

                	 
      	
                  OncoSeed
      Sterile Convenience Pack (SCP)

                	 
      	
                  EA.

                	 
      	
                  1

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                
	
                  7000

                	 
      	
                  RAPID
      Strand (Strand of 10 Seeds)

                	 
      	
                  EA.

                	 
      	
                  1

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                
	
                  7007-I125NRVG

                	 
      	
                  RAPID
      Strand Loaded in Oncura Needle

                	 
      	
                  EA.

                	 
      	
                  1

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                
	
                  7008-I125NRVG

                	 
      	
                  RAPID
      Strand Loaded In Customer Needles

                	 
      	
                  EA.

                	 
      	
                  1

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                
	
                  7009-I125NRVG

                	 
      	
                  RAPID
      Strand Loaded In Other Needles

                	 
      	
                  EA.

                	 
      	
                  1

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                
	
                  I125RSRX-RND

                	 
      	
                  RAPID
      Strand RX loaded in Round Hub Needle

                	 
      	
                  EA.

                	 
      	
                  1

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                
	
                  I125RSRX-SQR

                	 
      	
                  RAPID
      Strand RX loaded in Square Hub Needle

                	 
      	
                  EA.

                	 
      	
                  1

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                
	
                  I125RSRX-CUST

                	 
      	
                  RAPID
      Strand RX loaded in Customer Provided Needle

                	 
      	
                  EA.

                	 
      	
                  1

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                
	
                  6716-I125CCPNSR

                	 
      	
                  OncoSeed
      Stranded Loaded CCP Needle Round Hub

                	 
      	
                  EA.

                	 
      	
                  1

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                
	
                  6716-I125CCPNSS

                	 
      	
                  OncoSeed
      Stranded Loaded CCP Needle Square Hub

                	 
      	
                  EA.

                	 
      	
                  1

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                
	
                  6719-RSRL

                	 
      	
                  OncoSeed
      Stranded in Needle (Vari-StrandTM)

                	 
      	
                  EA.

                	 
      	
                  1

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                
	
                  671010-I125-RCAA

                	 
      	
                  OncoSeed
      Loaded Reuseable Mick Cartridge 10% Assay/Sterilized

                	 
      	
                  CTG.

                	 
      	
                  1

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                
	
                  671010-I125DCA

                	 
      	
                  OncoSeed
      Loaded Disposable Mick Cartridge 10% Assay

                	 
      	
                  CTG.

                	 
      	
                  1

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                
	
                  671010-I125DCAA

                	 
      	
                  OncoSeed
      Loaded Disposable Mick Cartridge 10% Assay/Sterilized

                	 
      	
                  CTG.

                	 
      	
                  1

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                
	
                  671010-I125SV

                	 
      	
                  OncoSeed
      Loose 10% Assay Charge

                	 
      	
                  EA.

                	 
      	
                  1

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                
	
                  671010-I125SVG

                	 
      	
                  OncoSeed
      Loose 10% Assay/Sterilized

                	 
      	
                  EA.

                	 
      	
                  1

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                
	
                  671100-I125SV

                	 
      	
                  OncoSeed
      Loose 100% Assay Charge

                	 
      	
                  EA.

                	 
      	
                  1

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                	 
      	
                  [**]

                
	
                  671100-I125SVG

                	
                    

                	
                  OncoSeed
      Loose 100% Assay/Sterilized

                	
                    

                	
                  EA.

                	
                    

                	
                  1

                	
                    

                	
                  [**]

                	
                    

                	
                  [**]

                	
                    

                	
                  [**]

                	
                    

                	
                  [**]

                

        

      

    

      
      

      [**]Certain
information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

    

     

    
      *These products shall be paid monthly
but all reconciliations shall be made on a quarterly basis.

       

    

    
      
        
           

        

        
          1

          
            

          

        

        
           

        

      

    

    
    

    

    
    

    Exhibit
1.11

    

    125
PRODUCTS & PRICING*

    CANADA

     

    
      
        
          
            	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	 
      	
                    Quarterly
      Rebate

                  
	
                    Product
      Code

                  	 
      	
                    Product

                  	 
      	
                    UOM

                  	 
      	
                    UOM

                    Qty.

                  	 
      	
                    Price

                  	 
      	
                    Tier
      1

                    <
      [**]
      Seeds

                  	 
      	
                    Tier
      2

                    [**]

                    Seeds

                  	 
      	
                    Tier
      3

                    >
      [**] 

                    Seeds

                  
	

                    6711

                  	 
      	

                    OncoSeed
      Individual Seed

                  	 
      	
                    EA.

                  	 
      	
                    1

                  	 
      	

                    [**]

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  
	
                    6711C

                  	 
      	
                    OncoSeed
      Individual Calibrated Seed

                  	 
      	
                    EA.

                  	 
      	
                    1

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  
	
                    6717-I125NVG

                  	 
      	
                    OncoSeed
      Loaded in Oncura Needle

                  	 
      	
                    EA.

                  	 
      	
                    1

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  
	
                    6719-I125NVG

                  	 
      	
                    OncoSeed
      Loaded in Other Specified Needles

                  	 
      	
                    EA.

                  	 
      	
                    1

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  
	
                    6719-RL

                  	 
      	
                    OncoSeed
      Preloaded in Needle (Vari-LoadTM)

                  	 
      	
                    EA.

                  	 
      	
                    1

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  
	
                    6715

                  	 
      	
                    OncoSeed
      Sterile Convenience Pack (SCP)

                  	 
      	
                    CTG.

                  	 
      	
                    15

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  
	
                    6788

                  	 
      	
                    OncoSeed
      Sterile Convenience Pack (SCP)

                  	 
      	
                    EA.

                  	 
      	
                    1

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  
	
                    7000

                  	 
      	
                    RAPID
      Strand (Strand of 10 Seeds)

                  	 
      	
                    EA.

                  	 
      	
                    1

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  
	
                    7007-I125NRVG

                  	 
      	
                    RAPID
      Strand Loaded in Oncura Needle

                  	 
      	
                    EA.

                  	 
      	
                    1

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  
	
                    7008-I125NRVG

                  	 
      	
                    RAPID
      Strand Loaded In Customer Needles

                  	 
      	
                    EA.

                  	 
      	
                    1

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  
	
                    I125RSRX-RND

                  	 
      	
                    RAPID
      Strand RX loaded in Round Hub Needle

                  	 
      	
                    EA.

                  	 
      	
                    1

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  
	
                    6717-I125CCPNSS

                  	 
      	
                    OncoSeed
      Stranded Loaded CCP Needle Square Hub

                  	 
      	
                    EA.

                  	 
      	
                    1

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  	 
      	
                    [**]

                  
	
                    6719-RSRL

                  	
                      

                  	
                    OncoSeed
      Stranded in Needle (Vari-StrandTM)

                  	
                      

                  	
                    EA.

                  	
                      

                  	
                    1

                  	
                      

                  	
                    [**]

                  	
                      

                  	
                    [**]

                  	
                      

                  	
                    [**]

                  	
                      

                  	
                    [**]

                  

          

        

      

    

     

    
      
        

      

      [**]Certain
information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

    

    
    

    
        

      *These products shall be paid
monthly but all reconciliations shall be made on a quarterly basis.

       

    

    
      
        
           

        

        
          2

          
            

          

        

        
           

        

      

    

    
    

    
   

    Attachments

    

    I-125
Activity & Availability Schedule

    

    
      
        
          	
                  Median mCi

                	 
      	
                  Median Air Kerma

                
	
                  0.234

                	 
      	
                  0.297

                
	
                  0.254

                	 
      	
                  0.323

                
	
                  0.275

                	 
      	
                  0.349

                
	
                  0.299

                	 
      	
                  0.380

                
	
                  0.324

                	 
      	
                  0.411

                
	
                  0.352

                	 
      	
                  0.447

                
	
                  0.382

                	 
      	
                  0.485

                
	
                  0.414

                	 
      	
                  0.526

                
	
                  0.449

                	 
      	
                  0.570

                
	
                  0.487

                	 
      	
                  0.618

                
	
                  0.529

                	 
      	
                  0.672

                
	
                  0.574

                	 
      	
                  0.729

                
	
                  0.623

                	 
      	
                  0.791

                
	
                  0.676

                	 
      	
                  0.859

                
	
                  0.733

                	 
      	
                  0.931

                
	
                  0.796

                	 
      	
                  1.011

                

        

      

    

    

    *OncoSeed
is packaged with labeling information on air kerma strength and apparent
activity per seed, total air kerma strength and apparent activity, reference
date, number of seeds, and order I.D.

    Air
kerma strength is specified in units of microGray meter squared per hour
(uGym(2)/h), and apparent activity have units of milliCurie (mCi)

    

    
      
        
           

        

        
          1

          
            

          

        

        
           

        

      

    

    

    
      
  

    

    
      
        
          
            
              
                
                  	
                          Oncura I-125 Seed Calibration
      Guide

                        
	
                          Order

                          Activity

                        	 
      	
                          (mCi)

                        	 
      	
                              Decay
      Formula:

                        	 
      	
                          (EXP(-(LN(2)*t)/59.43))*Order
      Activity

                        
	
                          s

                        	 
      	 
      	 
      	
                          Tuesday
      Delivery is 1st available activity for Friday
  Calibration

                        
	
                          FRI.

                        	 
      	
                          SAT.

                        	 
      	
                          SUN.

                        	 
      	
                          MON.

                        	 
      	
                          TUES.

                        	 
      	
                          WED.

                        	 
      	
                          THUR.

                        	 
      	
                          FRI.

                        	 
      	 
      
	
                          0.937

                        	 
      	
                          0.926

                        	 
      	
                          0.915

                        	 
      	
                          0.905

                        	 
      	
                          0.894

                        	 
      	
                          0.884

                        	 
      	
                          0.874

                        	 
      	
                          0.863

                        	 
      	 
      
	
                          0.863

                        	 
      	
                          0.853

                        	 
      	
                          0.843

                        	 
      	
                          0.833

                        	 
      	
                          0.824

                        	 
      	
                          0.814

                        	 
      	
                          0.805

                        	 
      	
                          0.796

                        	 
      	 
      
	
                          0.796

                        	 
      	
                          0.787

                        	 
      	
                          0.778

                        	 
      	
                          0.769

                        	 
      	
                          0.760

                        	 
      	
                          0.751

                        	 
      	
                          0.742

                        	 
      	
                          0.733

                        	 
      	 
      
	
                          0.733

                        	 
      	
                          0.725

                        	 
      	
                          0.716

                        	 
      	
                          0.708

                        	 
      	
                          0.700

                        	 
      	
                          0.691

                        	 
      	
                          0.683

                        	 
      	
                          0.676

                        	 
      	 
      
	
                          0.676

                        	 
      	
                          0.668

                        	 
      	
                          0.660

                        	 
      	
                          0.653

                        	 
      	
                          0.645

                        	 
      	
                          0.638

                        	 
      	
                          0.630

                        	 
      	
                          0.623

                        	 
      	 
      
	
                          0.623

                        	 
      	
                          0.616

                        	 
      	
                          0.609

                        	 
      	
                          0.602

                        	 
      	
                          0.595

                        	 
      	
                          0.588

                        	 
      	
                          0.581

                        	 
      	
                          0.574

                        	 
      	 
      
	
                          0.574

                        	 
      	
                          0.567

                        	 
      	
                          0.561

                        	 
      	
                          0.554

                        	 
      	
                          0.548

                        	 
      	
                          0.541

                        	 
      	
                          0.535

                        	 
      	
                          0.529

                        	 
      	
                          Sterile
      Convenience Pack

                        
	
                          0.529

                        	 
      	
                          0.523

                        	 
      	
                          0.517

                        	 
      	
                          0.511

                        	 
      	
                          0.505

                        	 
      	
                          0.499

                        	 
      	
                          0.493

                        	 
      	
                          0.487

                        	 
      	 
      
	
                          0.487

                        	 
      	
                          0.481

                        	 
      	
                          0.476

                        	 
      	
                          0.470

                        	 
      	
                          0.465

                        	 
      	
                          0.459

                        	 
      	
                          0.454

                        	 
      	
                          0.449

                        	 
      	 
      
	
                          0.449

                        	 
      	
                          0.444

                        	 
      	
                          0.439

                        	 
      	
                          0.434

                        	 
      	
                          0.429

                        	 
      	
                          0.424

                        	 
      	
                          0.419

                        	 
      	
                          0.414

                        	 
      	 
      
	
                          0.414

                        	 
      	
                          0.409

                        	 
      	
                          0.404

                        	 
      	
                          0.400

                        	 
      	
                          0.395

                        	 
      	
                          0.391

                        	 
      	
                          0.386

                        	 
      	
                          0.382

                        	 
      	 
      
	
                          0.382

                        	 
      	
                          0.378

                        	 
      	
                          0.373

                        	 
      	
                          0.369

                        	 
      	
                          0.365

                        	 
      	
                          0.360

                        	 
      	
                          0.356

                        	 
      	
                          0.352

                        	 
      	 
      
	
                          0.352

                        	 
      	
                          0.348

                        	 
      	
                          0.344

                        	 
      	
                          0.340

                        	 
      	
                          0.336

                        	 
      	
                          0.332

                        	 
      	
                          0.328

                        	 
      	
                          0.324

                        	 
      	 
      
	
                          0.324

                        	 
      	
                          0.320

                        	 
      	
                          0.317

                        	 
      	
                          0.313

                        	 
      	
                          0.309

                        	 
      	
                          0.306

                        	 
      	
                          0.302

                        	 
      	
                          0.299

                        	 
      	 
      
	
                          0.299

                        	 
      	
                          0.296

                        	 
      	
                          0.292

                        	 
      	
                          0.289

                        	 
      	
                          0.285

                        	 
      	
                          0.282

                        	 
      	
                          0.279

                        	 
      	
                          0.275

                        	 
      	 
      
	
                          0.275

                        	 
      	
                          0.272

                        	 
      	
                          0.269

                        	 
      	
                          0.266

                        	 
      	
                          0.262

                        	 
      	
                          0.259

                        	 
      	
                          0.256

                        	 
      	
                          0.254

                        	 
      	 
      
	
                          0.254

                        	 
      	
                          0.251

                        	 
      	
                          0.248

                        	 
      	
                          0.245

                        	 
      	
                          0.242

                        	 
      	
                          0.240

                        	 
      	
                          0.237

                        	 
      	
                          0.234

                        	 
      	 
      
	
                          0.234

                        	 
      	
                          0.231

                        	 
      	
                          0.229

                        	 
      	
                          0.226

                        	 
      	
                          0.223

                        	 
      	
                          0.221

                        	 
      	
                          0.218

                        	 
      	
                          0.215

                        	 
      	 
      
	
                          0.215

                        	 
      	
                          0.213

                        	 
      	
                          0.210

                        	 
      	
                          0.208

                        	 
      	
                          0.205

                        	 
      	
                          0.203

                        	 
      	
                          0.200

                        	 
      	
                          0.199

                        	 
      	 
      
	
                          0.199

                        	 
      	
                          0.197

                        	 
      	
                          0.194

                        	 
      	
                          0.192

                        	 
      	
                          0.190

                        	 
      	
                          0.188

                        	 
      	
                          0.186

                        	 
      	
                          0.183

                        	
                            

                        	 
      

                

              

            

          

        

      

    

    

    
      
        
           

        

        
          2

          
            

          

        

        
           

        

      

    

    

    
  

    Product
Order, Availability & Return Schedule

    

    Standard Delivery Service:
 All direct non
custom I-125 orders are shipped for next day delivery. For custom services,
ONCURA requests that all orders are placed by 4:00 PM CT three (3) business days
before the implant.  Please allow five (5) business days for custom
stranding services.

    

    Standard Delivery Fees: $40
per order.

    

    Order Information: All non
custom I-125 product orders are shipped directly from G.E. Healthcare’s
manufacturing facility in North Arlington Heights, IL, or via a designated
radiopharmacy. Orders can be placed by
calling Oncura @ 1-800-633-4123,
or 1-800-228-0126.
FAX orders can be placed @ 1-800-826-9863.  Electronic
orders can be placed through TherapyOrdersUSA@Oncura.com.
All orders are shipped via FEDEX for overnight delivery.

    

    Returned
Goods Policy:

    

    Returns
for Disposal - No
return fee.

    

    Return
for Credit - 100%
credit to account if a patient is unable to undergo treatment, based on a
medical condition not previously identified, or for any unforeseen circumstances
beyond physician or facility control, and if Oncura customer service is notified
by 4:00 PM CT on scheduled day of implant. Please note that a signed physician
statement supporting this decision is required. Oncura Products may be returned
for credit or disposal with prior authorization from our Customer Service
Department. The required Return Material Authorization (RMA) number and
applicable shipping labels will be provided by the Oncura Customer Support Group
(800) 633-4123. All approved credits will be issued within 30 days after receipt
of product.  Products returned for credit should be returned unused in
the original packaging and in good condition.

    

    
      
        
           

        

        
          3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00166-of-00352.parquet"}]]